Thrombophilia, preeclampsia and other pregnancy complications;Trombofilija, preeklampsija i ostale komplikacije trudnoće

Acta Medica Croatica

Volumn 63, Issue 4, 2009, Pages 297-305

  Vučić, Nikša ^a   Frleta, Marina ^a   Petrović, Davor ^b   Ostojić, Vedran ^a  

^a Croatian Academy of Medical Sciences   (Croatia)

^b UNIVERSITY HOSPITAL OSIJEK   (Croatia)

Author keywords

APLA syndrome; Complications of pregnancy; Preeclampsia; Thrombophilia

Indexed keywords

ACETYLSALICYLIC ACID; ANTIVITAMIN K; BLOOD CLOTTING FACTOR 5 LEIDEN; CARDIOLIPIN ANTIBODY; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; LUPUS ANTICOAGULANT; PHOSPHOLIPID ANTIBODY; PROTEIN S;

CARDIOVASCULAR RISK; DEEP VEIN THROMBOSIS; FETUS WASTAGE; GENE MUTATION; HETEROZYGOSITY; HUMAN; HYPERHOMOCYSTEINEMIA; INTRAUTERINE GROWTH RETARDATION; LUNG EMBOLISM; PREECLAMPSIA; PREGNANCY COMPLICATION; PROPHYLAXIS; PROTEIN DEFICIENCY; REVIEW; THROMBOPHILIA;

FEMALE; FIBRINOLYTIC AGENTS; HEART VALVE PROSTHESIS; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; PRE-ECLAMPSIA; PREGNANCY; PREGNANCY COMPLICATIONS, HEMATOLOGIC; THROMBOEMBOLISM; THROMBOPHILIA;

EID: 74049113219     PISSN: 13300164     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (81)

1. Hatasaka HH. Recurrent miscarriage epidemiologic factors, definitions, and incidence. Clin Obstet Gynecol 1994; 37: 625-34.
2. Brenner B. Clinical management of thrombophiliarelated placental vascular complications. Blood 2004; 103: 4003-9.
3. Greer IA. Thrombophilia: implications for pregnancy outcome. Thromb Res 2003; 109: 73-81.
4. Vučć N, Cala K, Rancic I, Pticar R. Therapy and prevention of deep venous thrombosis and pulmonary embolism in gynecology and obstetrics. Acta Med Croatica 2003; 57: 123-30.
5. Robertson L, Wu O, Langhorne P i sur. The thrombosis risk and economic assessment of thrombophilia screening (treats) study: thrombophilia in pregnancy; a systematic review. Br J Haematol 2005; 132: 171-96.
6. Ginsberg JS, Brill-Edwards P, Johnston M isur. Relationship of antiphospholipid antibodies to pregnancy loss in patients with systemic lupus erythematosis: a cross-sectional study. Blood 1992; 80: 975-80.
7. Laskin CA, Bomardier C, Hannah MR i sur. Prednisone and aspirin in women with autoantibodies and unexplained recurrent fetal loss. N Engl J Med 1997; 337: 148-53.
8. Rai RS, Clifford K, Cohen H i sur. High prospective fetal loss rate in untreated pregnancies of women with recurrent miscarriage and antiphospholipid antibodies. Hum Reprod 1995; 10: 3301-4.
9. Empson M, Lassere M, Craig J i sur. Prevention of recurrent miscarriage for women with antiphospholipid antibody or lupus anticoagulant. Cochrane Database Syst Rev 2005; CD002859
10. Djelmiš J, Radončić E, Ivanišević M. Antiphospholipid antibody syndrome and fetal outcome. Acta Med Croatica 2001; 55: 123-30.
11. Branch DW, Andres R, Digre KB i sur. The association of antiphospholipid antibodies with severe preeclampsia. Obstet Gynecol 1989; 73: 541-5.
12. Yasuda M, Takakuwa K, Tokunaga A I sur. Prospective studies of the association between anticardiolipin antibody and outcome of pregnancy. Obstet Gynecol 1995; 86: 555-9.
13. Polzin WJ, Kopelman JN, Robinson RD. Antiphropholipid antibodies in women at risk for preeclampsia. Obstet Gynecol 2001; 184: 825-34.
14. Lockwood CJ, Romero R, Feinberg RF i sur. The prevalence and biologic significance of lupus anticoagulant and anticardiolipin antibodies in a general obstetric population. Am J Obstet Gynecol 1989; 161: 369-73.
15. Lockshin MD, Druzin ML, Goei S i sur. Antibody to anticardiolipin as a predictor of fetal distress or death in pregnant women with systemic lupus erythematosus. N Engl J Med 1985; 313: 152-6.
16. Reece EA, Gabrielli S, Cullen MT i sur. Recurrent adverse pregnancy outcome and antiphospholipid antibodies. Am J Obstet Gynecol 1990; 163: 162-9.
17. Milliez J, Lelong F, Bayani N i sur. The prevalence of autoantibodies during third-trimester pregnancy complicated by hypertension or idiopathic fetal growth retardation. Am J Obstet Gynecol 1991; 165: 51-6.
18. El-Roeiy A, Myers SA, Gleicher N. The relationship between autoantibodies and intrauterine growth retardation in hypertensive disorders of pregnancy. Am J Obstet Gynecol 1991; 164: 1253-61.
19. Chan WS, Anand S, Ginsberg JS. Anticoagulation of pregnant women with mechanical heart valves: a systematic review of the literature. Arch Intern Med 2000; 160: 191-6.
20. Pabinger I. Thrombophilia and its impact on pregnancy. Thromb Res 2009;123 Suppl 3: S16-21.
21. Bates SH, Greer IA, Pabinger I, Sofaer S, Hirsh J. Venous thromboembolism, thrombophilia, antithrombotic therapy, and pregnancy. Chest 2008; 844S-8879S
22. Lissalde-Lavigne G, Fabbro-Peray P, Cochery-Nouvellon E i sur. Factor V Leiden and prothrombin G20210A polymorphisms as risk factors for miscarriage during a first intended pregnancy: the matched case-control 'NOHA first' study. J Thromb Haemost 2005; 3: 2178-84.
23. Dizon-Townson D, Miller C, Sibai B, et al for the National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network. The relationship of the factor V Leiden mutation and pregnancy outcomes for mother and fetus. Obstet Gynecol 2005; 106: 517-24.
24. Rudick B, Irene Su H, Sammel MD, Kovalevsky G, Shaunik A, Barnhart K. Is factor V Leiden mutation a cause of in vitro fertilization failure? Fertil Steril. 2009 May 20. [Epub ahead of print]
25. Many A, Elad R, Yaron Y i sur. Third-trimester unexplained intrauterine fetal death is associated with inherited thrombophilia. Obstet Gynecol 2002; 99: 684-7.
26. Hefler L, Jirecek S, Heim K i sur. Genetic polymorphisms associated with thrombophilia and vascular disease in women with unexplained late intrauterine fetal death: a multicenter study. J Soc Gynecol Invest 2004; 11: 42-4.
27. De Maat MP, Jansen MW, Hille ET i sur. Preeclampsia and its interaction with common variants in thrombophilia genes. J Thromb Haemost 2004; 2: 1588-93.
28. Mello G, Parretti E, Marozio L i sur. Thrombophilia is significantly associated with severe preeclampsia: results of a large-scale, case-controlled study. Hypertension 2005; 46: 1270-4.
29. Morrison ER, Miedzybrodzka ZH, Campbell DM i sur. Prothrombotic genotypes are not associated with preeclampsia and gestational hypertension: results from a large population-based study and systematic review. Thromb Haemost 2002; 87: 779-85.
30. Lindhoff-Last E, Luxembourg B. Evidence-based indications for thrombophilia screening. Vasa 2008; 37: 19-30.
31. Kutteh WH. Antiphospholipid antibody-associated recurrent pregnancy loss: treatment with heparin and low-dose aspirin is superior to low-dose aspirin alone. Am J Obstet Gynecol 1996; 174: 1584-9.
32. Rai R, Cohen H, Dave M i sur. Randomised controlled trial of aspirin and aspirin plus heparin in pregnant women with recurrent miscarriage associated with phospholipid antibodies (or antiphospholipid antibodies). BMJ 1997; 314: 253-7.
33. Franklin RD, Kutteh WH. Antiphospholipid antibodies (APLA) and recurrent pregnancy loss: treating a unique APA positive population. Hum Reprod 2002; 17: 2981-5.
34. Kutteh WH, Ermel LD. A clinical trial for the treatment of antiphospholipid antibody-associated recurrent pregnancy loss with lower dose heparin and aspirin. Am J Reprod Immunol 1996; 35: 402-7.
35. Cowchock S, Reece EA. Do low-risk pregnant women with antiphospholipid antibodies need to be treated? Organizing Group of the Antiphospholipid Antibody Treatment Trial. Am J Obstet Gynecol 1997; 176: 1099-1100.
36. Pattison NS, Chamley LW, Birdsall M i sur. Does aspirin have a role in improving pregnancy outcome for women with the antiphospholipid syndrome? A randomized controlled trial. Am J Obstet Gynecol 2000; 183: 1008-12.
37. Tulppala M, Marttunen M, Soderstrom-Anttila V i sur. Low-dose aspirin in prevention of miscarriage in women with unexplained or autoimmune related recurrent miscarriage: effect on prostacyclin and thromboxane A2 production. Hum Reprod 1997; 12: 1567-72.
38. Laskin CA, Bombardier C, Hannah ME i sur. Prednisone and aspirin in women with autoantibodies and unexplained recurrent fetal loss. N Engl J Med 1997; 337: 148-53.
39. Farquharson RG, Quenby S, Greaves M. Antiphospholipid syndrome in pregnancy: a randomized, controlled trial of treatment. Obstet Gynecol 2002; 100: 408-13.
40. Laskin CA, Spitzer KA, Clark CA i sur. Low molecular weight heparin and aspirin for recurrent pregnancy loss: results from the randomized, controlled HepASA Trial. J Rheumatol 2009; 36: 279-87.
41. Triolo G, Ferrante A, Ciccia F i sur. Randomized study of subcutaneous low molecular weight heparin plus aspirin versus intravenous immunoglobulin in the treatment of recurrent fetal loss associated with antiphospholipid antibodies. Arthritis Rheum 2003; 48: 728-31.
42. Noble LS, Kutteh WH, Lashey N i sur. Antiphospholipid antibodies associated with recurrent pregnancy loss: prospective, multicenter, controlled pilot study comparing treatment with low-molecular-weight heparin versus unfractionated heparin. Fertil Steril 2005; 83: 684-90.
43. Stephenson MD, Ballem PJ, Tsang P i sur. Treatment of antiphospholipid antibody syndrome (APS) in pregnancy: a randomized pilot trial comparing low molecular weight heparin to unfractionated heparin. J Obstet Gynaecol Can 2004; 26: 729-34.
44. Gris JC, Quere I, Monpeyroux F i sur. Case-control study of the frequency of thrombophilic disorders in couples with late fetal loss and no thrombotic antecedent: the Nimes Obstetricians and Haematologists Study 5 (NOHA5). Thromb Haemost 1999; 81: 891-9.
45. Brenner B, Hoffman R, Blumenfeld Z i sur. Gestational outcome in thrombophilic women with recurrent pregnancy loss treated by enoxaparin. Thromb Haemost 2000; 83: 693-7.
46. Carp H, Dolitzky M, Inbal A. Thromboprophylaxis improves the live birth rate in women with consecutive recurrent miscarriages and hereditary thrombophilia. J Thromb Haemost 2003; 1: 433-8.
47. Kupferminc MJ, Fait G, Many A i sur. Low-molecular-weight heparin for the prevention of obstetric complications in women with thrombophilias. Hypertens Pregnancy 2001; 20: 35-44.
48. Brenner B, Bar J, Ellis M i sur. Effects of enoxaparin on late pregnancy complications and neonatal outcome in women with recurrent pregnancy loss and thrombophilia: results from the Live-Enox study. Fertil Steril 2005; 84: 770-3.
49. Brenner B, Hoffman R, Carp H i sur. Efficacy and safety of two doses of enoxaparin in women with thrombophilia and recurrent pregnancy loss: the LIVE-ENOX study. J Thromb Haemost 2005; 3: 227-9.
50. Walker ID, Kujovich JL, Greer IA i sur. The use of LMWH in pregnancies at risk: new evidence or perception? J Thromb Haemost 2005; 3: 778-93.
51. Lindqvist PG, Merlo J. Low molecular weight heparin for repeated pregnancy loss: is it based on solid evidence? J Thromb Haemost 2005; 3: 221-3; BMJ 2005; 330: 565-71.
52. Gris JC, Mercier E, Quere I i sur. Low-molecular-weight heparin versus low-dose aspirin in women with one fetal loss and a constitutional thrombophilic disorder. Blood 2004; 103: 3695-9.
53. Tzafettas J, Petropoulos P, Psarra A i sur. Early antiplatelet and antithrombotic therapy in patients with a history of recurrent miscarriages of known and unknown aetiology. Eur J Obstet Gynaecol Reprod Biol 2005; 120: 22-6.
54. Santoro R, Iannaccaro P, Prejanò S, Muleo G. Efficacy and safety of the long-term administration of low-molecular-weight heparins in pregnancy. Blood Coagul Fibrinolysis 2009 Apr 7. [Epub ahead of print]
55. Greer IA, Nelson Piercy C. Low molecular weight heparins for thromboprophylaxis and treatment of venous thromboembolism in pregnancy: a systematic review of safety and efficacy. Blood 2005; 106: 401-7.
56. Warren JE, Simonsen SE, Branch DW, Porter TF, Silver RM. Thromboprophylaxis and pregnancy outcomes in asymptomatic women with inherited thrombophilias. Am J Obstet Gynecol. 2009; 200: 281.e1-5. Epub 2008 Dec 27.
57. Koga K, Osuga Y, Yoshino O i sur. Elevated serum soluble vascular endothelial growth factor receptor 1 (sVEGFR-1) levels in women with preeclampsia. J Clin Endocrinol Metab 2003; 88: 2348-51.
58. Bussolino F, Benedetto C, Massobrio M i sur. Maternal vascular prostacyclin activity in pre-eclapsia. Lancet 1980;2: 702.
59. Ashworth JR, Baker PH, Warren AY i sur. Mechanisms of endothelium-dependent relation in myometrial resistance vessels and their alteration in preeclampsia. Hypertens Pregnancy 1999; 18: 57-71.
60. Roberts JS. Endothelial dysfunction in preeclampsia. Semin Reprod Endocrinol 1998; 16: 5-15.
61. Sheppard BL, Bonnar J. An ultrastructural study of uteroplacental spiral arteries in hypertensive and normotensive pregnancy and fetal growth retardation. Br J Obstet Gynaecol 1981; 88: 695-705.
62. Duckitt K, Harringtion D. Risk factors for preeclampsia at antenatal booking: systematic review of controlled studies. BMJ 2005; 330: 565-71.
63. Hnat MD, Sibai BM, Caritis S i sur. Perinatal outcome in women with recurrent preeclampsia compared with women who develop preeclampsia as nulliparae. Am J Obstet Gynecol 2002; 186: 422-6.
64. Duley L, Henderson-Smart DJ, Knight M i sur. Antiplatelet agents for preventing preeclampsia and its complications: Cochrane Database Systematic Rev 2003; CD004659
65. Hills FA, Abrahams VM, Gonzalez-Timon B i sur. Heparin prevents programmed cell death in human trophoblast. Mol Hum Reprod 2006; 12: 237-43.
66. Kalk JJ, Huisjes AJ, de Groot CJ i sur. Recurrence rate of preeclampsia in women with thrombophilia influenced by low-molecular-weight heparin treatment? Neth J Med 2004; 62: 83-7.
67. Mello G, Parretti E, Fatini C i sur. Low-molecular-weight heparin lowers the recurrence rate of preeclampsia and restores the physiological vascular changes in angiotensin-converting enzyme DD women. Hypertension 2005; 45: 86-91.
68. Rey E, Garneau P, David M i sur. Dalteparin for the prevention of recurrence of placental-mediated complications of pregnancy in women without thrombophilia: a pilot randomized controlled trial. J Thromb Haemost 2009; 7: 58-64. Epub 2008 Nov 20
69. Chan WS, Anand S, Ginsberg JS. Anticoagulation of pregnant women with mechanical heart valves: a systematic review of the literature. Arch Intern Med 2000; 160: 191-6.
70. Al-Lawati AAM, Venkitraman M, Al-Delaime T i sur. Pregnancy and mechanical heart valves replacement: dilemma of anticoagulation. Eur J Cardiothorac Surg 2002; 22: 223-7.
71. Geelani MA, Singh S, Verma A i sur. Anticoagulation in patients with mechanical valves during pregnancy. Asian Cardiovasc Thorac Ann 2005; 13: 30-3.
72. Nassar AH, Hobeika EM, Abd Essamad HM i sur. Pregnancy outcome in women with prosthetic heart valves. Am J Obstet Gynecol 2004; 191: 1009-13.
73. Arnaout MS, Kazma H, Khalil A i sur. Is there a safe anticoagulation protocol for pregnant women with prosthetic valves? Clin Exp Obstet Gynecol 1998; 25: 101-4.
74. Lee LH, Liaaux PC, Ng AS. Low molecular-weight heparin for thromboprophylaxis during pregnancy in 2 patients with mechanical mitral valves replacement [letter]. Thromb Haemost 1996; 76: 6288-6630.
75. Roberts N, Ross D, Flint SK i sur. Thromboembolism in pregnant women with mechanical prosthetic heart valves anticoagulated with low molecular weight heparin. Br J Obstet Gynaecol 2001; 108: 327-9.
76. Leyh RG, Fischer S, Ruhparwar A i sur. Anticoagulation for prosthetic heart valves during pregnancy: is low-molecular-weight heparin an alternative. Eur J Cardiothorac Surg 2002; 21: 577-9.
77. Mahesh B, Evans S, Bryan AJ. Failure of low molecular weight heparin in the prevention of prosthetic mitral valve thrombosis during pregnancy: case report and review of options for anticoagulation. J Heart Valve Dis 2002; 11: 745-50.
78. Lev-Ran O, Kramer A, Gurevitch J i sur. Low-molecular-weight heparin for prosthetic heart valves: treatment failure. Ann Thorac Surg 2000; 69: 264-5.
79. Shapira Y, Sagie A, Battler A. Low-molecular-weight heparin for the treatment of patients with mechanical heart valves. Clin Cardiol 2002; 25: 323-7.
80. Lovenox Injection (package insert). Bridgewater, NJ: Aventis Pharmaceuticals, 2004
81. Oran B, Lee-Parritz A, Ansell J. Low molecular weight heparin for the prophylaxis of thromboembolism in women with prosthetic mechanical heart valves during pregnancy. Thromb Haemost 2004; 92: 747-51.